Active targeting of block copolymer micelles with trastuzumab fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4229-4241

  Hoang, Bryan ^a   Ekdawi, Sandra N ^a   Reilly, Raymond M ^a,b,c   Allen, Christine ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

active targeting; block copolymer micelles; HER2; nanotechnology

Indexed keywords

BLOCK COPOLYMER MICELLE; COPOLYMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; INDIUM 111; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CAPILLARY DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICELLES; MICROSCOPY, FLUORESCENCE; MODELS, THEORETICAL; NANOTECHNOLOGY; NUCLEAR LOCALIZATION SIGNALS; POLYMERS; RECEPTOR, ERBB-2;

EID: 84887346589     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400315p     Document Type: Article

References (67)

1. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer Br. J. Cancer 2004, 90, 2085-91
2. Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 2007, 18 (12) 2009-2014
3. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 2004, 91, 1775-81
4. Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, Y.; Nakahama, H.; Matsumura, Y. A Phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 2007, 97 (2) 170-6
5. Allen, C.; Maysinger, D.; Eisenberg, A. Nanoengineering block copolymer aggregates for drug delivery Colloids Surf., B: Interfaces 1999, 16, 3-27
6. Kwon, G. S.; Kataoka, K. Block-Copolymer Micelles as Long-Circulating Drug Vehicles Adv. Drug Delivery Rev. 1995, 16, 295-309
7. Harada, A.; Kataoka, K. Supramolecular assemblies of block copolymers in aqueous media as aanocontainers relevant to biological applications Prog. Polym. Sci. 2006, 31, 949-82
8. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-84
9. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46, 6387-92
10. Vlerken, L. E.; Amiji, M. M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery Expert Opin. Drug Delivery 2006, 3, 205-16
11. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2002, 2 (10) 750-63
12. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (7) 2586-91
13. Fang, C.; Shi, B.; Pei, Y. Y.; Hong, M. H.; Wu, J.; Chen, H. Z. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size Eur. J. Pharm. Sci. 2006, 27 (1) 27-36
14. Khalid, M. N.; Simard, P.; Hoarau, D.; Dragomir, A.; Leroux, J. C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors Pharm. Res. 2006, 23 (4) 752-8
15. McNeeley, K. M.; Annapragada, A.; Bellamkonda, R. V. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma Nanotechnology 2007, 18, 1-11
16. Kwon, I. K.; Lee, S. C.; Han, B.; Park, K. Analysis on the current status of targeted drug delivery to tumors J. Controlled Release 2012, 164 (2) 108-14
17. Kirpotin, D. M.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 2006, 66, 6732-40
18. Laginha, K. M.; Moase, E. H.; Yu, N.; Huang, A.; Allen, T. M. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer J. Drug Target. 2008, 16, 605-10
19. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 2005, 65, 11631-8
20. Pirollo, K. F.; Chang, E. H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 2008, 26, 552-8
21. Ross, J. S.; Slodkowska, E. A.; Symmans, W. F.; Pusztai, L.; Ravdin, P. M.; Hortobaqyi, G. N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 2009, 14 (4) 320-68
22. Owens, M. A.; Horten, B. C.; Da Silma, M. M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin. Br. Cancer 2004, 5, 63-9
23. Harris, A. L.; Nicholson, S.; Sainsbury, J. R. C.; Farndon, J.; Wright, C. Epidermal Growth-Factor Receptors in Breast-Cancer-Association with Early Relapse and Death, Poor Response to Hormones and Interactions with Neu J. Steroid Biochem. Mol. Biol. 1989, 34 (1-6) 123-131
24. Wang, S. L.; Li, Y. X.; Song, Y. W.; Wang, W. H.; Jin, J.; Liu, Y. P.; Liu, X. F.; Yu, Z. H. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy Int. J. Radiat. Oncol. Biol. Phys. 2011, 80 (4) 1095-101
25. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235 (4785) 177-82
26. Baak, J. P.; Chin, D.; van Diest, P. J.; Ortiz, R.; Matze-Cok, P.; Bacus, S. S. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer Lab. Invest. 1991, 64 (2) 215-23
27. Costantini, D.; McLarty, K.; Lee, H.; Done, S. J.; Vallis, K.; Reilly, R. M. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts J. Nucl. Med. 2010, 51 (7) 1084-91
28. 111In-Bn-DTPA-Nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (herceptin)-resistant breast cancer Br. Cancer Res. Treat. 2012, 135 (1) 189-200
29. Hoang, B.; Reilly, R. M.; Allen, C. Block copolymer micelles target auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells Biomacromolecules 2012, 13, 455-65
30. Buchegger, F.; Perillo-Adamer, F.; Dupertuis, Y. M.; Delaloye, A. B. Auger radiation targeted into DNA: a therapy perspective Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 1352-63
31. Paine, P. L.; Moore, L. C.; Horowitz, S. B. Nuclear envelope permeability Nature 1975, 254, 109-114
32. Mikhail, A. S.; Allen, C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissye and cellular levels J. Controlled Release 2009, 138 (3) 214-23
33. Zeng, F. Q.; Allen, C. Synthesis of Carboxy-Functionalized Heterobifunctional Poly(ethylene glycol) by a Thiol-Anionic Polymerization Method Macromolecules 2006, 39, 6391-8
34. Kim, M. S.; Hyun, H.; Cho, Y. H.; Seo, K. S.; Jang, W. Y.; Kim, S. K.; Khang, G.; Lee, H. B. Preparation of methoxy poly(ethyleneglycol)-block- poly(caprolactone) via activated monomer mechanism and examination of micellar characterization Polym. Bull. 2005, 55, 149-56
35. Liu, J.; Zeng, F.; Allen, C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration Eur. J. Pharm. Biopharm. 2007, 65, 309-19
36. Zeng, F. Q.; Lee, H.; Allen, C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics Bioconjugate Chem. 2006, 17, 399-409
37. Lee, H.; Hoang, B.; Fonge, H.; Reilly, R. M.; Allen, C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels Pharm. Res. 2010, 27, 2343-55
38. 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging Mol. Pharmaceutics 2009, 6, 581-92
39. 111In-labeled trastuzumab (herceptin) modified with nuclear localizing sequences (NLS): A novel auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer J. Nucl. Med. 2007, 48 (8) 1357-68
40. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; Tinevez, J.-Y.; White, D. J.; Hartenstein, V.; Eliceiri, K.; Tomancak, P.; Cardona, A. Fiji: an open-source platform for biological-image analysis Nat. Methods 2012, 9, 676-82
41. Lee, H.; Fonge, H.; Hoang, B.; Reilly, R. M.; Allen, C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles Mol. Pharmaceutics 2010, 7, 1195-208
42. 111In] DTPA-hEGF Nucl. Med. Biol. 2007, 34, 887-96
43. Elbayoumi, T. A.; Torchilin, V. P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies Eur. J. Nucl. Med. Mol. Imag. 2006, 33, 1196-1205
44. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies Br. J. Cancer 2000, 83, 232-238
45. Liu, J.; Zeng, F.; Allen, C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration Eur. J. Pharm. Biopharm. 2007, 65, 309-319
46. Novakova, K.; Laznicek, M.; Rypacek, F.; Machova, L. I-125-labeled PLA/PEO block copolymer: biodistribution studies in rats J. Bioact. Compat. Polym. 2002, 17, 285-296
47. 177Lu-pegylated liposomes conjugates in tumor-bearing mice Nucl. Instrum. Methods 2006, 569, 533-537
48. Tang, Y.; Scollard, D.; Chen, P.; Wang, J.; Holloway, C.; Reilly, R. M. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNICtrastuzumab (Herceptin) Fab fragments Nucl. Med. Commun. 2005, 26, 427-432
49. Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M. R.; Miyazono, K.; Uesaka, M.; Nishiyama, N.; Kataoka, K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size Nat. Nanotechnol. 2011, 6, 815-23
50. Hu, Q.; Gu, G.; Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Tu, Y.; Pang, Z.; Song, Q.; Yao, L.; Xia, H.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery Biomaterials 2013, 34, 1135-45
51. Jiang, X.; Xin, H.; Gu, J.; Xu, X.; Xia, W.; Chen, S.; Xie, Y.; Chen, L.; Chen, Y.; Sha, X.; Fang, X. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel Biomaterials 2013, 34, 1739-46
52. Kano, M. R.; Bae, Y.; Iwata, C.; Morishita, Y.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M.; Hirakawa, K.; Ouchi, Y.; Nishiyama, N.; Kataoka, K.; Miyazono, K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumours by inhibition of TGF-b signaling Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3460-5
53. Gillies, R. J.; Schornack, P. A.; Secomb, T. W.; Raghunand, N. Causes and effects of heterogeneous perfusion in tumors Neoplasia 1999, 1 (3) 197-207
54. Penault-Llorca, F.; Adelaide, J.; Houvenaeghel, G.; Hassoun, J.; Birnbaum, D.; Jacquemier, J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation J. Pathol. 1994, 173, 65-75
55. Subik, K.; Lee, J.-F.; Baxter, L.; Strzepek, T.; Costello, D.; Crowley, P.; XIng, L.; Hung, M.-C.; Bonfiglio, T.; Hicks, D. G.; Tang, P. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical analysis in breast cancer cell lines Breast Cancer (Auckl) 2010, 4, 35-41
56. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 2010, 7 (11) 653-64
57. Chauhan, V. P.; Stylianopoulos, T.; Boucher, Y.; Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies Annu. Rev. Chem. Biomol. 2011, 2, 281-98
58. Pante, N.; Kann, M. Nuclear pore complex is able to transport macromolecules with diameters of ∼39 nm Mol. Biol. Cell 2002, 13, 425-34
59. Misra, R.; Sahoo, S. K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur. J. Pharm. Sci. 2010, 39, 152-63
60. Yu, J.; Xie, X.; Zheng, M.; Yu, L.; Zhang, L.; Zhao, J.; Jiang, D.; Che, X. Fabrication and characterization of nuclear localization signal-conjugated glycol chitosan micelles for improving the nuclear delivery of doxorubicin Int. J. Nanomed. 2012, 7, 5079-90
61. Aronov, O.; Horowitz, A. T.; Gabizon, A.; Fuertes, M. A.; Perez, J. M.; Gibson, D. Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues Bioconjugate Chem. 2004, 15 (4) 814-23
62. Sethuraman, V. A.; Bae, Y. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors J. Controlled Release 2007, 118 (2) 216-24
63. Symens, N.; Soenen, S. J.; Rejman, J.; Braeckmans, K.; DeSmedt, S. C.; Remaut, K. Intracellular partitioning of cell organelles and extraneuos nanoparticles during mitosis Adv. Drug Delivery Rev. 2012, 64, 78-94
64. Fenton, B. M.; Paoni, S. F.; Lee, J.; Koch, C. J.; Lord, E. M. Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements Br. J. Cancer 1999, 79 (3-4) 464-71
65. 111In-Labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR J. Nucl. Med. 2000, 41, 429-438
66. Chen, T. J.; Cheng, T. H.; Chen, C. Y.; Hsu, S. C.; Cheng, T. L.; Liu, G. C.; Wang, Y. M. Targeted herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI J. Biol. Inorg. Chem. 2009, 14 (2) 253-60
67. Wang, Y.; Liu, X.; Nakamura, K.; Chen, L.; Rusckowski, M.; Hnatowich, D. Improving in vivo delivery of antisense MORF using Herceptin/streptavidin nanoparticle Eur. J. Nucl. Med. Mol. Imag. 2009, 36 (12) 1977-86